Jazz Pharmaceuticals plc

NASDAQ:JAZZ   4:00:00 PM EDT
116.08
+3.78 (+3.37%)
7:06:29 PM EDT: $118.10 +2.02 (+1.74%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.02B
Current PE14.57
Forward PE 24.23
2yr Forward PE 5.38
See more stats
Estimates Current Quarter
Revenue$1.05 Billion
Adjusted EPS-$7.42
See more estimates
10-Day MA$111.50
50-Day MA$108.59
200-Day MA$118.09
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.